Weight Loss Intervention for Breast Cancer Recurrence Prevention
Trial Summary
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, it does mention that hormonal therapy and certain other treatments are acceptable during the trial. It's best to discuss your specific medications with the trial team.
What data supports the effectiveness of the treatment for weight loss intervention in breast cancer recurrence prevention?
Is the Weight Loss Intervention for Breast Cancer Recurrence Prevention generally safe for humans?
How does this weight loss treatment for breast cancer recurrence prevention differ from other treatments?
This weight loss treatment is unique because it focuses on a comprehensive approach combining dietary changes, physical activity, and behavior modification, specifically targeting overweight or obese women with breast cancer to prevent recurrence. Unlike standard cancer treatments, this intervention is delivered through telephone-based coaching and aims for a 10% weight loss, which could potentially become a standard part of breast cancer care.23111213
What is the purpose of this trial?
This randomized phase III trial studies whether weight loss in overweight and obese women may prevent breast cancer from coming back (recurrence). Previous studies have found that women who are overweight or obese when their breast cancer is found (diagnosed) have a greater risk of their breast cancer recurring, as compared to women who were thinner when their cancer was diagnosed. This study aims to test whether overweight or obese women who take part in a weight loss program after being diagnosed with breast cancer have a lower rate of cancer recurrence as compared to women who do not take part in the weight loss program. This study will help to show whether weight loss programs should be a part of breast cancer treatment.
Research Team
Jennifer Ligibel, MD
Principal Investigator
Dana-Farber Cancer Institute
Eligibility Criteria
Women over 18 with invasive breast cancer diagnosed within the last 14 months, who have completed initial treatments and are overweight (BMI ≥27 kg/m2). Participants must be able to walk two blocks and read English. They should not have had other cancers in the past 4 years, severe diseases that limit life expectancy or activity, or serious digestive issues.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a 2-year telephone-based weight loss intervention focusing on caloric restriction and physical activity, supplemented with print and online materials
Follow-up
Participants are monitored for safety and effectiveness after treatment, with follow-up every 6 months for the first 3 years and then annually until 10 years from registration
Treatment Details
Interventions
- Health Education Program
- Weight Loss Intervention
Find a Clinic Near You
Who Is Running the Clinical Trial?
Alliance for Clinical Trials in Oncology
Lead Sponsor
NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP)
Collaborator
Canadian Cancer Trials Group
Collaborator
National Cancer Institute (NCI)
Collaborator
Division of Cancer Control
Collaborator